Abstract:
The invention provides an aqueous totarol extract formulation. More specifically, provided herein is an aqueous based totarol extract formulation that has utility in treating human and/or animal infections such as mastitis and metritis; wounds and which formulations can be used in sprays, shampoos, sanitizers and the like.
Abstract:
A method of converting Compound A (1,3-dehydro-cyclopenta[1]phenanthren-2-one) to Compound C (1H-cyclopenta[1]phenanthren) in situ in a single reactor is disclosed.
Abstract:
The present invention provides convergent processes for preparing (-)-beta-elemene, (-)-beta-elemenal, (-)-beta-elemenol, and (-)-beta-elemene fluoride and analogues thereof. Also provided are intermediates useful for preparing (-)-beta-elemene. The present invention further provides novel compositions based on analogues of (-)-beta-elemene, (-)-beta-elemenal, (-)-beta-elemenol, (-)-beta-elemene fluoride and methods for the treatment of cancer, such as brain tumor, lung cancer, breast cancer, prostate cancer, ovarian cancer, colorectal cancer, gastric intestional cancer, and stomach cancer. The inventors propose a combination therapy using 1) one or more of the following anti-cancer agents: including, but not limited to, Cisplatin, 5-FU, Taxol, Taxol derivatives, and any anti-cancer agent, and 2) one or more of the following (-)-beta-elemene and its analogs, including (-)-beta-elemene, (-)-beta-elemenol, (-)-beta-elemenol, (-)-beta-elemene fluoride, and their analogs, and (-)-beta-elemene's intermediate in its chemical synthesis, for the treatment of cancer, especially for the treatment of brain tumor, lung cancer, ovarian cancer, bladder cancer, cervical cancer,. colon cancer, breast cancer, and prostate cancer.
Abstract:
The present invention provides non-steroidal compounds of formula (I) which are selective modulators (i.e., agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides intermediates and processes for preparing these compounds.
Abstract:
New active compounds are provided for the preparation of pharmaceutical compositions for medicinal use in general, and for use in dermatology, oncology, and the treatment of kidney, liver and nervous system disorders, and in which is present the group of formula (I) having three six-carbon condensed homocyclic rings including an aromatic central ring and two saturated or unsaturated aliphatic side rings in the meta position with respect to the aromatic central ring, and wherein the lateral substitutes R1 and R2 are alkyl groups with a carbon number of 1 to 4; both the aliphatic side rings also possibly having one or more further lateral substitutes.
Abstract:
A process for the synthesis of (±)-(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-octahydrophenanthrene-2,6-dicarbonitrile ("TBE-31"), which is useful for the treatment of various diseases and disorder in mammals. (±)-8a-(Hydroxymethyl)-1,4a-dimethyl-2,3,4,4a,6,7,8,8a,9,10-decahydrophenanthren-2-ol; (±)-8a-(Hydroxymethyl)-1,4a-dimethyl-4,4a,6,7,8,8a,9,10-octahydrophenanthren-2(3H)-one; (±)-(2R,4aS,8aS)-8a-(Hydroxymethyl)-1,4a-dimethyl-2,3,4,4a,6,7,8,8a,9,10-decahydrophenanthren-2-ol; (±)-(2S,4aS,8aS)-8a-(Hydroxymethyl)-1,4a-dimethyl-2,3,4,4a,6,7,8,8a,9,10-decahydrophenanthren-2-ol; and (±)-(4aS,8aS)-8a-(Hydroxymethyl)-1,4a-dimethyl-4,4a,6,7,8,8a,9,10-octahydrophenanthren-2(3H)-one (4).
Abstract:
This invention discloses diterpenes class of novel compounds of general formula I from a novel source. More particularly the invention relates to extracts /fractions containing pimarane diterpenes from Anisochillus (Lamiaceae), useful for prevention, treatment, inhibition or controlling growth and proliferation of mycobacterial activity in mammals. The invention further relates to extracts, fractions standardized to diterpenes class of novel compounds useful for the treatment of cancers.
Abstract:
The subject invention provides a binuclear metal complex having structure (I) wherein M1, and M2 are independently selected from the group consisting of Fe, Co, Mn and Ru; wherein m and n are independently +2 or +3; wherein R1, R2, R3, R4, R5 and R6 are independently a linear C1-C6 alkyl, C5-C6 cycloalkyl, phenyl, etc.; wherein (i) R1 and R2, (ii) R3 and R4, or (iii) R5 and R6 independently and optionally are linked covalently and together with the respective adjoining C atom comprise a spirocyclic ring; wherein i, j and k are integers such that 2